Refractory Burkitt Lymphoma Responding to an Accelerated Ramp-up of Glofitamab With Polatuzumab [0.03%]
接受戈利妥单抗联合波洛妥珠单抗加速爬坡治疗的难治性伯基特淋巴瘤患者的疗效
Syed Abdul Mannan Shah,Aaron Cumpston,Huda Elzahrany et al.
Syed Abdul Mannan Shah et al.
SOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas [0.03%]
SOHO前沿更新及下一步问题 | 解析侵袭性B细胞淋巴瘤的变革性问题
Gonca Ozcan,Mark Roschewski
Gonca Ozcan
Large B-cell lymphoma (LBCL) is a heterogeneous disease for which anthracycline-based chemoimmunotherapy cures most patients. However, a substantial minority of patients experience refractory disease or relapse, and outcomes remain poor. Im...
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma [0.03%]
新型化疗方案与传统化疗方案治疗复发或难治性经典型霍奇金淋巴瘤的疗效比较研究
Daniel Ermann,Victoria Vardell,Erin Zacholski et al.
Daniel Ermann et al.
Background: Limited data exists comparing the efficacy of novel therapies containing brentuximab vedotin and/or checkpoint inhibitors to standard chemotherapy as treatment for relapsed/refractory classical Hodgkin Lymphom...
Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab [0.03%]
两例接受Elranatamab治疗的进行性多灶性白质脑病(PML)患者报告
Oliver Tomkins,Rea Grace Maamari,Sam Douthwaite et al.
Oliver Tomkins et al.
Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients [0.03%]
种族和民族对多发性骨髓瘤患者生存的社会驱动因素分析
Christen M Dillard,Ashwath Gurumurthi,Hans C Lee et al.
Christen M Dillard et al.
Background: Despite the introduction of novel antimyeloma therapies, Black and Hispanic individuals with multiple myeloma (MM) often experience worse survival outcomes than White counterparts, influenced not only by disea...
Real-World Insights Into Acute promyelocytic leukemia (APL) in Egypt in the Absence of Arsenic Trioxide (ATO): Clinical Characteristics, Outcomes and Risk Factors for Early Mortality: A Single Center Study [0.03%]
埃及真实世界急性早幼粒细胞白血病的临床特点、预后及早期死亡的影响因素：一项单中心研究（未使用三氧化砷）
Yasmine Shaaban,Dina N Laimon,Esraa Jamal
Yasmine Shaaban
Background: Acute promyelocytic leukemia (APL) is a rare but highly curable subtype of acute leukemia. Despite therapeutic advances, early death (ED) within 30 days of diagnosis remains a major challenge affecting APL out...
An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study [0.03%]
来那度胺和蛋白酶体抑制剂初治多发性骨髓瘤患者的治疗模式及疗效的观察性研究：Base-MM研究
Klaus Martin Kortüm,James Farrell,Olivia Ashman et al.
Klaus Martin Kortüm et al.
Introduction: Most patients with relapsed or refractory multiple myeloma (RRMM) have previously received lenalidomide (LEN) and proteasome inhibitors (PIs). This real-world study describes treatment patterns and clinical ...
CNS Prophylaxis With Intrathecal Cytarabine Post Allogeneic Stem Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: A Monocentric Experience [0.03%]
allo-HSCT后成人急性淋巴细胞白血病患者预防中枢神经系统复发的鞘内注射阿糖胞苷方案的研究经验
Jean El Cheikh,Sally Chahine,Ali Tarhini et al.
Jean El Cheikh et al.
Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series [0.03%]
终末期肾病血液透析患者的CAR-T细胞治疗安全性和耐受性：一系列病例研究
Zohaib Ahmed,Walid Hamouche,Syed O Ahmad et al.
Zohaib Ahmed et al.
Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features [0.03%]
BTKi中断后CLL的里奇特综合征转化的系统性回顾：临床、生物学及病理特征分析
Javier Marco-Ayala,María Dolores García Malo,Francisco J Ortuño et al.
Javier Marco-Ayala et al.
Background: Pseudo-Richter transformation (pseudo-RT) is a rare and recently recognized phenomenon characterized by a transient large B-cell proliferation occurring shortly after interruption of Bruton tyrosine kinase inh...